HC Wainwright & Co. Reiterates Buy on Processa Pharma, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Processa Pharma (NASDAQ:PCSA) and maintained a price target of $8.
August 01, 2024 | 10:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Processa Pharma and maintained a price target of $8.
The reiteration of a Buy rating and the maintenance of a price target at $8 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100